



Pharmaids Pharmaceuticals Limited

Date: 18.09.2025

To
The Corporate Relation Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001

Dear Sir / Madam,

Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018

Subject: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Pursuant to Regulation 30 of the Listing Regulations, we hereby inform that pursuant to the resolution passed by the shareholders of the Company through postal ballot on August 14, 2025, the Company has, on September 18, 2025, executed an Exit /Reconstitution Deed ("Exit Deed") for sale of its entire 66.50% partnership stake in Anugraha Chemicals ("the Firm") to Mrs. Sneha Hadimani for an aggregate cash consideration of Rs.6,65,000/-. Consequently, the Company has ceased to be a partner in the Firm and accordingly, the Firm has ceased to be a material subsidiary of the Company.

The proposal of disinvestment was approved by the Board of Directors earlier at its meeting held on July 04, 2025, as duly mentioned in our intimation about outcome of the said meeting of the Board by passing an enabling resolution.

Further, in continuation of our earlier submission dated January 25, 2023, regarding the Investment Agreement entered into by the Company for acquisition of its stake in the Firm, we wish to inform you that, pursuant to the completion of the said disinvestment, the Company has also executed a Termination Agreement today, thereby terminating the said Investment Agreement.

The details required under Regulation 30 of the Listing Regulations, read with the SEBI Circular dated November 11, 2024, are provided in Annexure A. Further, the disclosure under Para 5 of Part B of Schedule III of the Listing Regulations is also disclosed in Annexure B.

Kindly take the same on your record and oblige.

Thanking You

For Pharmaids Pharmaceuticals Limited

Prasanna Subramanya Bhat
(Company Secretary & Compliance Officer)

PHARMAIDS PHARMACEUTICALS LIMITED (CIN: L52520KA1989PLC173979)

Registered Office: Unit #201, Brigade Rubix, 20/14, HMT Factory Road, Peenya Plantation, Bangalore 560013 INDIA

Phone: 080-49784319 Email: compliance@pharmaids.com WEB: www.pharmaids.com



Details required under the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024;

Sl. No	Particular	Details
	Name of the Company/Body Corporate ceased to subsidiary	Anugraha Chemicals (“the Firm”)
a	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year;	<p>Anugraha Chemicals Contribution in Consolidated Revenue as on March 31, 2025:</p> <p>Amount: Rs.13,40,05,450/- Percentage (%): 68.91</p> <p>Anugraha Chemicals Contribution in Consolidated Net worth as on March 31, 2025:</p> <p>Amount: Rs. 3,74,15,092/- Percentage (%): 6.80</p>
b	Date on which the agreement for sale has been entered into	<p>Exit agreement on September 18, 2025.</p> <p>(The date of entering into the agreement has been considered as the date of signature by the last signing party)</p>
c	The expected date of completion of sale/disposal	The transaction is already completed. September 18, 2025.
d	Consideration received from such sale/disposal	*Rs. 6,65,000/- (Rupees Six Lakh Sixty five Thousand Only).
e	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	<p>Mr. Sourabh Hadimani and Mrs. Sneha Hadimani, nominee of Mr. Sourabh Hadimani.</p> <p>The buyer does not belong to the promoter/ promoter group /group companies of the Company.</p>
f	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length	The transaction will not fall within related party transactions.



Pharmaids Pharmaceuticals Limited

g	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations	<p>Yes. The aforesaid transaction is not part of a Scheme of Arrangement.</p> <p>Further, the sale of partnership interest in the firm, attract the terms of regulation 37A of the Listing Regulations, as it constitute an undertaking or substantially the whole of the undertaking for the Company under section 180(1)(a) of the Companies Act, 2013.</p> <p>The Company have obtained the shareholders' approval by means of passing special resolution under Section 180(1)(a) and 188 of the Companies Act, 2013 through postal ballot on August 14, 2025.</p>
h	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not Applicable

For Pharmaids Pharmaceuticals Limited

Prasanna Subramanya Bhat
(Company Secretary & Compliance officer)

*Clarification Note:

It may be noted that in our earlier intimations regarding the proposed sale of stake, the total consideration was disclosed as ₹10,50,00,000/- (Rupees Ten Crore Fifty Lakh only). As clarified therein, this amount represented the aggregate value, arrived at after considering (i) the Company's capital contribution made in multiple tranches towards acquisition of partnership interest, (ii) loans extended to Anugraha Chemicals amounting to ₹3,06,75,000/- (Rupees Three Crore Six Lakh Seventy Five Thousand only) along with accrued interest adjustments, (iii) sharing of accumulated losses as a partner, and (iv) ₹26,34,712/- (Rupees Twenty Six Lakh Thirty Four Thousand Seven Hundred and Twelve only) towards settlement of employee-related dues.

In this regard, the Company has presently received ₹6,65,000/- (Rupees Six Lakh Sixty five Thousand only) representing the consideration for sale of its partnership stake (capital contribution). The balance amounts towards loans, interest adjustments and other dues shall be received in due course.



Details required under the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024;

Sl. No	Particular	Details
a	Name(s) of parties with whom the agreement is entered.	a. Pharmaids Pharmaceuticals Limited (the “Company”), b. Anugraha Chemicals (the “Firm”) and c. Mr. Sourabh S Hadimani (the “Partner”) All the above (a) to (c) are collectively referred as “Parties”
b	Purpose of entering into the agreement	The Parties have executed the Termination Agreement to terminate (with immediate effect) the Investment Agreement dated January 25, 2023, executed between the Company, the firm and the partner.
c	Shareholding, if any, in the entity with whom the agreement is executed	Not Applicable. The Investment Agreement is terminated.
d	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.	Termination with immediate effect of: a) the Investment Agreement which governed their inter-se relationship and their rights & obligations as partner of Anugraha Chemicals with respect to the operation and management of the firm; and b) all other agreements, arrangements and contracts existing between the parties.
e	Whether the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship	The parties does not belong to the promoter/ promoter group /group companies of the Company.
f	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”	The transaction will not fall within related party transactions.
g	In case of issuance of shares to the parties, details of issue price, class of shares issued	Not Applicable.



Pharmaids Pharmaceuticals Limited

h	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc;	Not Applicable.
i	In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s):	
a	name of parties to the agreement;	a. Pharmaids Pharmaceuticals Limited (the “Company”), b. Anugraha Chemicals (the “Firm”) and c. Mr. Sourabh S Hadimani (the “Partner”)
b	nature of the agreement	Termination Agreement
c	date of execution of the agreement;	September 18, 2025.
d	details of amendment and impact thereof or reasons of termination and impact thereof.	Reasons of termination: Parties mutually agreed to terminate the Investment Agreement as per the termination clause of the agreement. Impact of termination: Termination with immediate effect of: a) the Investment Agreement which governed their inter-se relationship and their rights & obligations as partner of Anugraha Chemicals with respect to the operation and management of the firm; and b) all other agreements, arrangements and contracts existing between the parties. The Company has ceased to be a partner in the Firm and accordingly, the Firm has ceased to be a material subsidiary of the Company.

For Pharmaids Pharmaceuticals Limited

Prasanna Subramanya Bhat
(Company Secretary & Compliance officer)